Cargando…

Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease

To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD w...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Yong Ki, Suh, Kyo II, Choi, Sang Jeon, Lee, Hong Kyu, Kim, Chung Yong, Koh, Chang-Soon, Min, Hun Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534913/
https://www.ncbi.nlm.nih.gov/pubmed/3154815
http://dx.doi.org/10.3904/kjim.1987.2.1.37
_version_ 1782385526736683008
author Min, Yong Ki
Suh, Kyo II
Choi, Sang Jeon
Lee, Hong Kyu
Kim, Chung Yong
Koh, Chang-Soon
Min, Hun Ki
author_facet Min, Yong Ki
Suh, Kyo II
Choi, Sang Jeon
Lee, Hong Kyu
Kim, Chung Yong
Koh, Chang-Soon
Min, Hun Ki
author_sort Min, Yong Ki
collection PubMed
description To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD who had fasting plasma glucose(FBS) of less than 100 mg/dl. The patients with CLD who had normal FBS(FBS less than 100 mg/dl) were divided into two groups by the National Diabetes Data Group Criteria: one with abnormal glucose tolerance (abnormal GTT, Group 1) and the other with normal glucose tolerance (normal GTT. Group 2). Group 1 patients showed significantly higher plasma insulin (p<0.02 and p<0.01, respectively) and C-peptide concentrations (p<0.01) in the fasting state and 2 hours after a 75gram oral glucose loading (PP2) than group 2 patients. Urinary excretion of C-peptide per 24 hours was also higher in group 1 patients than in group 2 patients (p<0.01). Group 2 patients demonstrated similar plasma insulin, C-peptide and urinary excretion of C-peptide per 24 hours to normal subjects (p>0.05). These results suggest that patients with CLD who had normal FBS can be divided into two groups by oral glucose tolerance test(GTT) and those with abnormal GTT have hyperinsulinemia the mechanism of which is insulin hypersecretion from pancreatic B-cell.
format Online
Article
Text
id pubmed-4534913
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-45349132015-10-02 Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease Min, Yong Ki Suh, Kyo II Choi, Sang Jeon Lee, Hong Kyu Kim, Chung Yong Koh, Chang-Soon Min, Hun Ki Korean J Intern Med Original Article To elucidate the mechanism of glucose intolerance in patients with chronic liver disease(CLD), we measured the levels of plasma glucose, insulin and C-peptide during oral glucose tolerance test and urinary excretion of C-peptide per 24 hours during a weight maintenance diet in 20 patients with CLD who had fasting plasma glucose(FBS) of less than 100 mg/dl. The patients with CLD who had normal FBS(FBS less than 100 mg/dl) were divided into two groups by the National Diabetes Data Group Criteria: one with abnormal glucose tolerance (abnormal GTT, Group 1) and the other with normal glucose tolerance (normal GTT. Group 2). Group 1 patients showed significantly higher plasma insulin (p<0.02 and p<0.01, respectively) and C-peptide concentrations (p<0.01) in the fasting state and 2 hours after a 75gram oral glucose loading (PP2) than group 2 patients. Urinary excretion of C-peptide per 24 hours was also higher in group 1 patients than in group 2 patients (p<0.01). Group 2 patients demonstrated similar plasma insulin, C-peptide and urinary excretion of C-peptide per 24 hours to normal subjects (p>0.05). These results suggest that patients with CLD who had normal FBS can be divided into two groups by oral glucose tolerance test(GTT) and those with abnormal GTT have hyperinsulinemia the mechanism of which is insulin hypersecretion from pancreatic B-cell. Korean Association of Internal Medicine 1987-01 /pmc/articles/PMC4534913/ /pubmed/3154815 http://dx.doi.org/10.3904/kjim.1987.2.1.37 Text en Copyright © 1987 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Min, Yong Ki
Suh, Kyo II
Choi, Sang Jeon
Lee, Hong Kyu
Kim, Chung Yong
Koh, Chang-Soon
Min, Hun Ki
Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title_full Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title_fullStr Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title_full_unstemmed Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title_short Glucose, Insulin and C-peptide Kinetics during an Oral Glucose Tolerance Test in Patients with Chronic Liver Disease
title_sort glucose, insulin and c-peptide kinetics during an oral glucose tolerance test in patients with chronic liver disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534913/
https://www.ncbi.nlm.nih.gov/pubmed/3154815
http://dx.doi.org/10.3904/kjim.1987.2.1.37
work_keys_str_mv AT minyongki glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT suhkyoii glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT choisangjeon glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT leehongkyu glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT kimchungyong glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT kohchangsoon glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease
AT minhunki glucoseinsulinandcpeptidekineticsduringanoralglucosetolerancetestinpatientswithchronicliverdisease